{"id":27232,"date":"2024-03-06T14:08:21","date_gmt":"2024-03-06T08:38:21","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=27232"},"modified":"2024-03-06T19:20:12","modified_gmt":"2024-03-06T13:50:12","slug":"aaaai-annual-meeting-highlights","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/aaaai-annual-meeting-highlights","title":{"rendered":"Major Highlights and Insights from the AAAAI Annual Meeting, 2024"},"content":{"rendered":"\n<p><strong>American Academy of Allergy, Asthma &amp; Immunology (AAAAI) 2024 <\/strong>annual meeting, is the premier educational event for allergists\/immunologists around the world that was held from <strong>February 23 to 26<\/strong> at the Walter E. Washington Convention Center this year. The American Academy of Allergy, Asthma &amp; Immunology (AAAAI) is the leading membership organization of more than 7,000 allergists\/immunologists (in the United States, Canada, and 72 other countries) and patients&#8217; trusted resource for allergies, asthma, and immune deficiency disorders.<\/p>\n\n\n\n<p><strong>Results of various promising emerging assets were presented during the recently concluded AAAAI conference. Some of the key highlights from the conference include:<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-chronic-spontaneous-urticaria-csu-highlights\"><strong>Chronic Spontaneous Urticaria (CSU) Highlights<\/strong><\/h2>\n\n\n\n<p>Major Pharma companies involved in presenting their Chronic Spontaneous Urticaria data readouts during the recently concluded AAAAI conference include <strong>Celldex Therapeutics, Novartis Pharmaceuticals, Sanofi, <\/strong>and others.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novartis<\/strong> presented efficacy and safety results of <strong>REMIX-1<\/strong> and <strong>REMIX-2<\/strong>. <strong>Remibrutinib <\/strong>demonstrated greater efficacy as compared to placebo, independent of prior exposure to anti-IgE biologics, in patients with CSU, with a favorable safety profile in both subgroups.<\/li>\n\n\n\n<li><strong>Celldex Therapeutics announced Top Line results from a Phase II trial in <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-spontaneous-urticaria-market\"><strong>Chronic Spontaneous Urticaria patients<\/strong><\/a><strong>\u2019 refractory to antihistamines, including patients with prior biologic experience. <\/strong>The study achieved its primary endpoint. Barzolvolimab administered at 150mg every 4 weeks and 300mg every 8 weeks showed a <strong>significant and meaningful improvement in Urticaria Activity Score over 7 days (UAS7)<\/strong> compared to the placebo after 12 weeks in patients suffering from Chronic Spontaneous Urticaria who were unresponsive to antihistamine treatment.<\/li>\n\n\n\n<li><strong>Sanofi presented the results of the RILECSU study carried out for the treatment of Chronic Spontaneous Urticaria in patients who remain symptomatic despite the use of h1 antihistamine. <\/strong>The initial phase of the RILECSU dose-ranging investigation in adults experiencing moderate to severe Chronic Spontaneous Urticaria exhibited effectiveness and swift onset of action with rilzabrutinib at a dosage of 400mg three times a day (TID). Rilzabrutinib also displayed a positive safety profile.<\/li>\n\n\n\n<li><strong>Hangzhou Highlightll Pharmaceuticals<\/strong> announced the safety and efficacy results of <strong>TLL-018<\/strong>. The drug was well tolerated and showed high efficacy in <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-spontaneous-urticaria-epidemiology-forecast\"><strong>moderate-to-severe Chronic Spontaneous Urticaria patients<\/strong><\/a> with inadequate response to high doses or a combination of antihistamine treatment.<\/li>\n\n\n\n<li><strong>Tezepelumab, <\/strong>a monoclonal antibody inhibiting thymic stromal lymphopoietin (TSLP), demonstrated continued reductions in Chronic Spontaneous Urticaria disease activity and biomarkers after treatment discontinuation in anti-IgE\u2013naive patients.<\/li>\n\n\n\n<li><strong>Novartis<\/strong> presented the results of <strong>LOU064<\/strong> in patients with chronic spontaneous urticaria (CSU) who have participated in study CLOU064A2201.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-hereditary-angioedema-hae-highlights\"><strong>Hereditary Angioedema (HAE) Highlights<\/strong><\/h2>\n\n\n\n<p>Key pharma companies involved in presenting <a href=\"https:\/\/www.delveinsight.com\/report-store\/hereditary-angioedema-market\"><strong>Hereditary Angioedema data readouts<\/strong><\/a> during the recent AAAAI conference are <strong>KalVista, Pharvaris <\/strong>and others.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sebetralstat<\/strong>,<strong> <\/strong>a novel oral plasma kallikrein inhibitor for on-demand treatment in hereditary angioedema was evaluated in the <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05259917\"><strong>KONFIDENT<\/strong><\/a> trial. This<strong> Phase III<\/strong> trial was the largest and most representative trial ever conducted in Hereditary Angioedema. The results showed that most patients given sebetralstat at either dose started experiencing symptom relief within two hours. Specifically, the median time to the beginning of symptom relief was <strong>1.61 hours at the lower dose<\/strong> and <strong>1.79 hours at the higher dose<\/strong>. KalVista plans to file for approval of the drug in the US, Japan and Europe this year.<\/li>\n\n\n\n<li>The integrated safety and efficacy results across <strong>Phase II, pivotal Phase III, and open-label extension (OLE) studies <\/strong>evaluating <strong>garadacimab (anti-activated factor XII monoclonal antibody)<\/strong> for hereditary angioedema prophylaxis were reported in the AAAAI 2024 conference. These results provides additional support for the strong effectiveness of garadacimab over a period exceeding one year for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/hereditary-angioedema-epidemiology-forecast\"><strong>prevention of hereditary angioedema<\/strong><\/a> in the long term, along with the favorable and consistent safety profile observed thus far.<\/li>\n\n\n\n<li>Positive results from the <strong>CHAPTER-1 Phase II Study of Deucrictibant<\/strong> for the prophylactic treatment of Hereditary Angioedema Attacks were presented at AAAAI 2024. Analysis of the primary endpoint revealed that deucrictibant led to a <strong>significant reduction in the monthly attack rate<\/strong> by <strong>84.5%<\/strong> for participants receiving a daily dose of 40 mg and by <strong>79.3%<\/strong> for those receiving a daily dose of 20 mg, compared to the placebo group. These results support the future development of deucrictibant, which could become the preferred option to both <a href=\"https:\/\/www.delveinsight.com\/report-store\/hereditary-angioedema-pipeline-insight\"><strong>treat and prevent Hereditary Angioedema attacks<\/strong><\/a>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-allergy-highlights\"><strong>Allergy Highlights<\/strong><\/h2>\n\n\n\n<p>Key pharma companies involved in presenting <a href=\"https:\/\/www.delveinsight.com\/report-store\/food-allergy-market-insights\"><strong>allergy data<\/strong><\/a> readouts during the recent AAAAI conference are <strong>InnoUp Farma,<\/strong> <strong>ARS Pharma<\/strong> and others.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>INP20 <\/strong>demonstrated its potential as an <strong>immunotherapy with immunostimulatory capacity <\/strong>as per the results presented at the AAAAI 2024 conference. INP20 exhibited strong activation of cells transfected with TLR2 and TLR4, with both receptors being synergistically activated in a highly potent manner.<\/li>\n\n\n\n<li><strong>Neffy\u2019s <\/strong>efficacy results of a <strong>Phase III trial<\/strong> carried out in patients who developed anaphylactic symptoms after oral food challenge (OFC) were presented at the AAAAI 2024 conference. Neffy, an epinephrine nasal spray, is in development as a needle-free alternative for treating severe allergic reactions. It possesses pharmacokinetic and pharmacodynamic profiles similar to approved epinephrine injection products. <strong>ARS Pharma<\/strong>, the developer of Neffy, is scheduled to release top-line findings from its repeat dose investigation of neffy under nasal allergen challenge circumstances in the initial quarter of 2024. It plans to resubmit its New Drug Application (NDA) around the middle of the first half of 2024. Following approval, the expected Prescription Drug User Fee Act (PDUFA) action date and subsequent launch in the United States are anticipated to occur in the middle of the second half of 2024.<\/li>\n<\/ul>\n\n\n\n<p>For more insights on these results and major breakthroughs from the global healthcare conference, you can visit the link:<strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" class=\"ek-link\">Healthcare Congress Intelligence And Conference Coverage<\/a><\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140447\/healthcare-conference-intelligence-services-1024x256.png\" alt=\"\" class=\"wp-image-27245\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140447\/healthcare-conference-intelligence-services-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140447\/healthcare-conference-intelligence-services-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140447\/healthcare-conference-intelligence-services-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140447\/healthcare-conference-intelligence-services-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140447\/healthcare-conference-intelligence-services-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140447\/healthcare-conference-intelligence-services-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140447\/healthcare-conference-intelligence-services.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>American Academy of Allergy, Asthma &amp; Immunology (AAAAI) 2024 annual meeting, is the premier educational event for allergists\/immunologists around the world that was held from February 23 to 26 at the Walter E. Washington Convention Center this year. The American Academy of Allergy, Asthma &amp; Immunology (AAAAI) is the leading membership organization of more than [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":27243,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[21854,21852,21853,6704,7465,19119,21183,11389,18919,21665,20007,1270,21855],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-27232","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-aaaai-2024","tag-aaaai-annual-meeting","tag-aaaai-annual-meeting-2024","tag-allergy","tag-allergy-market","tag-chronic-spontaneous-urticaria","tag-chronic-spontaneous-urticaria-market","tag-conference","tag-healthcare-conference","tag-healthcare-conference-2024","tag-healthcare-conferences","tag-hereditary-angioedema","tag-hereditary-angioedema-market","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AAAAI 2024 Annual Meeting | Major Highlights and Key Insights<\/title>\n<meta name=\"description\" content=\"AAAAI Annual Meeting 2024 coverage providing key insights into the latest advancements in allergy, asthma, and immunology segment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/aaaai-annual-meeting-highlights\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AAAAI 2024 Annual Meeting | Major Highlights and Key Insights\" \/>\n<meta property=\"og:description\" content=\"AAAAI Annual Meeting 2024 coverage providing key insights into the latest advancements in allergy, asthma, and immunology segment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/aaaai-annual-meeting-highlights\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-06T08:38:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-06T13:50:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140236\/aaaai-annual-meeting-highlights.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AAAAI 2024 Annual Meeting | Major Highlights and Key Insights","description":"AAAAI Annual Meeting 2024 coverage providing key insights into the latest advancements in allergy, asthma, and immunology segment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/aaaai-annual-meeting-highlights","og_locale":"en_US","og_type":"article","og_title":"AAAAI 2024 Annual Meeting | Major Highlights and Key Insights","og_description":"AAAAI Annual Meeting 2024 coverage providing key insights into the latest advancements in allergy, asthma, and immunology segment.","og_url":"https:\/\/www.delveinsight.com\/blog\/aaaai-annual-meeting-highlights","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-03-06T08:38:21+00:00","article_modified_time":"2024-03-06T13:50:12+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140236\/aaaai-annual-meeting-highlights.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/aaaai-annual-meeting-highlights","url":"https:\/\/www.delveinsight.com\/blog\/aaaai-annual-meeting-highlights","name":"AAAAI 2024 Annual Meeting | Major Highlights and Key Insights","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/aaaai-annual-meeting-highlights#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/aaaai-annual-meeting-highlights#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140236\/aaaai-annual-meeting-highlights.png","datePublished":"2024-03-06T08:38:21+00:00","dateModified":"2024-03-06T13:50:12+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"AAAAI Annual Meeting 2024 coverage providing key insights into the latest advancements in allergy, asthma, and immunology segment.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/aaaai-annual-meeting-highlights"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/aaaai-annual-meeting-highlights#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140236\/aaaai-annual-meeting-highlights.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140236\/aaaai-annual-meeting-highlights.png","width":466,"height":284,"caption":"AAAAI Annual Meeting Highlights"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/06140236\/aaaai-annual-meeting-highlights-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AAAAI 2024<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AAAAI Annual Meeting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AAAAI Annual Meeting 2024<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">allergy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">allergy market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Chronic Spontaneous Urticaria<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">chronic spontaneous urticaria market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Conference<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Healthcare Conference<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Healthcare Conference 2024<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Healthcare Conferences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Hereditary Angioedema<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Hereditary Angioedema Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AAAAI 2024<\/span>","<span class=\"advgb-post-tax-term\">AAAAI Annual Meeting<\/span>","<span class=\"advgb-post-tax-term\">AAAAI Annual Meeting 2024<\/span>","<span class=\"advgb-post-tax-term\">allergy<\/span>","<span class=\"advgb-post-tax-term\">allergy market<\/span>","<span class=\"advgb-post-tax-term\">Chronic Spontaneous Urticaria<\/span>","<span class=\"advgb-post-tax-term\">chronic spontaneous urticaria market<\/span>","<span class=\"advgb-post-tax-term\">Conference<\/span>","<span class=\"advgb-post-tax-term\">Healthcare Conference<\/span>","<span class=\"advgb-post-tax-term\">Healthcare Conference 2024<\/span>","<span class=\"advgb-post-tax-term\">Healthcare Conferences<\/span>","<span class=\"advgb-post-tax-term\">Hereditary Angioedema<\/span>","<span class=\"advgb-post-tax-term\">Hereditary Angioedema Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Mar 6, 2024","modified":"Updated on Mar 6, 2024"},"absolute_dates_time":{"created":"Posted on Mar 6, 2024 2:08 pm","modified":"Updated on Mar 6, 2024 7:20 pm"},"featured_img_caption":"AAAAI Annual Meeting Highlights\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=27232"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27232\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/27243"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=27232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=27232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=27232"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=27232"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=27232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}